中华放射肿瘤学杂志
中華放射腫瘤學雜誌
중화방사종류학잡지
CHINESE JOURNAL OF RADIATION ONCOLOGY
2009年
2期
96-100
,共5页
戴洪海%姬巍%王绿化%欧广飞%梁军%冯勤付%肖泽芬%陈东福%吕纪马%周宗玫%张红星%殷蔚伯
戴洪海%姬巍%王綠化%歐廣飛%樑軍%馮勤付%肖澤芬%陳東福%呂紀馬%週宗玫%張紅星%慇蔚伯
대홍해%희외%왕녹화%구엄비%량군%풍근부%초택분%진동복%려기마%주종매%장홍성%은위백
肺肿瘤/放射疗法%三维适形%常规分割%预后
肺腫瘤/放射療法%三維適形%常規分割%預後
폐종류/방사요법%삼유괄형%상규분할%예후
Lung neoplasms/radiotherapy%Three-dimensional conformal%Conventional frac-tionational%Prognosis
目的 回顾性比较非小细胞肺癌术后三维适形放疗(3DCRT)和常规放疗的疗效、失败模式及副反应.方法 分析3年余接受术后放疗的ⅠB～ⅢB期非小细胞肺癌患者162例,其中86例采用3DCRT,76例采用常规放疗.结果 总随访率91.5%,3DCRT和常规放疗的中位随访时间分别为29.4个月和33.8个月.3DCRT和常规放疗的1、2、3年无局部进展生存率分别为97.5%、83.2%、83.2%和84.3%、76.0%、65.6%(χ2=5.46,P=0.019),总生存率、无疾病进展生存率和无远转生存率均相似;总局部区域失败率分别为14.5%和33.3%(χ2=7.70 P=0.006),远处转移率两组相似.2～3级放射性肺炎发生率3DCRT显著低于常规放疗(11.6%:23.7% χ2=4.10,P=0.043).结论 术后放疗采用3DCRT技术比常规放疗技术能提高局部控制率,降低放疗相关副反应发生率.
目的 迴顧性比較非小細胞肺癌術後三維適形放療(3DCRT)和常規放療的療效、失敗模式及副反應.方法 分析3年餘接受術後放療的ⅠB～ⅢB期非小細胞肺癌患者162例,其中86例採用3DCRT,76例採用常規放療.結果 總隨訪率91.5%,3DCRT和常規放療的中位隨訪時間分彆為29.4箇月和33.8箇月.3DCRT和常規放療的1、2、3年無跼部進展生存率分彆為97.5%、83.2%、83.2%和84.3%、76.0%、65.6%(χ2=5.46,P=0.019),總生存率、無疾病進展生存率和無遠轉生存率均相似;總跼部區域失敗率分彆為14.5%和33.3%(χ2=7.70 P=0.006),遠處轉移率兩組相似.2～3級放射性肺炎髮生率3DCRT顯著低于常規放療(11.6%:23.7% χ2=4.10,P=0.043).結論 術後放療採用3DCRT技術比常規放療技術能提高跼部控製率,降低放療相關副反應髮生率.
목적 회고성비교비소세포폐암술후삼유괄형방료(3DCRT)화상규방료적료효、실패모식급부반응.방법 분석3년여접수술후방료적ⅠB～ⅢB기비소세포폐암환자162례,기중86례채용3DCRT,76례채용상규방료.결과 총수방솔91.5%,3DCRT화상규방료적중위수방시간분별위29.4개월화33.8개월.3DCRT화상규방료적1、2、3년무국부진전생존솔분별위97.5%、83.2%、83.2%화84.3%、76.0%、65.6%(χ2=5.46,P=0.019),총생존솔、무질병진전생존솔화무원전생존솔균상사;총국부구역실패솔분별위14.5%화33.3%(χ2=7.70 P=0.006),원처전이솔량조상사.2～3급방사성폐염발생솔3DCRT현저저우상규방료(11.6%:23.7% χ2=4.10,P=0.043).결론 술후방료채용3DCRT기술비상규방료기술능제고국부공제솔,강저방료상관부반응발생솔.
Objective To compare postoperative three-dimensional conformal radiotherapy (3DCRT) and conventional radiotherapy (CR) in patients with non-small-cell lung cancer (NSCLC). Methods From Nov. 2002 to Mar. 2006,162 patients with stage ⅠB～ⅢB NSCLC receiving postoperative radiotherapy in our department were restrospetcively analyzed. Among them,86 received 3DCRT and 76 re-ceived CR. The survival outcome, pattern of failure and treatment-related side effects in both groups were an-alyzed. Results The median follow-up was 29.4 months in the 3DCRT group and 24 months in the CR group. The 1-,2- and 3-year local-regional free survival was 97.5% ,83.2% and 83.2% in 3DCRT group, and 84.3% ,76.0% and 65.6% in CR group(χ2= 5.46, P = 0.019), respectively. No statistically signifi-cant difference was found in the overall survival, disease-free survival or distant metastasis-free survival be-tween the two groups. The local-regional failure rate was statistically different between the two groups (14.5% vs 33.3% ,χ2 =7.70,P =0.006). The incidence of distant metastasis in the two groups was simi-lar. Radiation pneumonitis of NCI CTC grade 2-3 occurred in 10 patients(11.6%)in 3DCRT group and 18 (23.7%) in CR group,which was statistically different(χ2 =4.10,P=0.043). Conclusions Postopera-tive 3DCRT for NSCLC provides a better local-regional control and lower incidence of radiation pneumonitis compared with CR.
